Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study - PubMed
5 hours ago
- #chemotherapy
- #clinical trial
- #prostate cancer
- The CASCARA Phase 2 Study evaluated cabazitaxel, carboplatin, and abiraterone with ADT in high-volume metastatic castration-sensitive prostate cancer (mCSPC).
- Primary endpoint: 84.6% of patients were free of PSA or radiographic progression at 12 months.
- Secondary outcomes included a 66.7% complete PSA response rate and 30.7% complete objective response rate.
- Overall survival at 12 months was 94.8%.
- HRR-mutated patients showed fewer complete PSA responses (33.3%) and inferior PFS compared to HRR-wildtype patients.
- Common side effects included fatigue, nausea, and diarrhea.
- The regimen was found feasible, safe, and efficacious, warranting further study in larger trials.